株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

麻酔効果:パイプライン製品の分析

Anesthetic Effect - Pipeline Review, H2 2017

発行 Global Markets Direct 商品コード 253649
出版日 ページ情報 英文 88 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.40円で換算しております。
Back to Top
麻酔効果:パイプライン製品の分析 Anesthetic Effect - Pipeline Review, H2 2017
出版日: 2017年09月12日 ページ情報: 英文 88 Pages
概要

麻酔効果によって意識が喪失します。合併症のリスクを高める主な要因として、喫煙や閉塞型睡眠時無呼吸症、肥満、高血圧、麻酔の副作用の病歴、医薬品へのアレルギー体質などが挙げられます。

当レポートでは、世界各国での麻酔効果治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

イントロダクション

  • 調査範囲

麻酔効果の概要

治療薬の開発

  • パイプライン製品の概要
  • 企業で開発中の治療薬
  • 大学/機関で研究中の治療薬
  • 企業で開発中の製品
  • 大学/機関で研究中の製品

麻酔効果:治療薬の評価

  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

麻酔効果の治療薬開発に従事している企業

  • 4P Therapeutics LLC
  • Biolab Farmaceutica Ltda
  • Drawbridge Pharmaceuticals Pty Ltd
  • Expanesthetics Inc
  • Jiangsu Hengrui Medicine Co Ltd
  • Lee's Pharmaceutical Holdings Ltd
  • Lipicard Technologies Ltd
  • NanoMedex Pharmaceuticals Inc
  • Paion AG
  • Phosphagenics Ltd
  • Physica Pharma
  • Primex Pharmaceuticals Oy
  • Proteus SA
  • Sphaera Pharma Pvt Ltd
  • Taiwan Liposome Company Ltd
  • The Medicines Company
  • WEX Pharmaceuticals Inc

薬剤プロファイル

麻酔効果:休止中のプロジェクト

麻酔効果:開発が中止された製品

麻酔効果:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9705IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Anesthetic Effect - Pipeline Review, H2 2017, provides an overview of the Anesthetic Effect (Central Nervous System) pipeline landscape.

Anesthetic effect causes a loss of consciousness. The factors that can increase risk of complications include smoking, obstructive sleep apnea, obesity, high blood pressure, history of adverse reactions to anesthesia and drug allergies.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Anesthetic Effect - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Anesthetic Effect (Central Nervous System)

List of TablesNumber of Products under Development for Anesthetic Effect, H2 2017 10Number of Products under Development by Companies, H2 2017 The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Anesthetic Effect (Central Nervous System) pipeline guide

List of TablesNumber of Products under Development for Anesthetic Effect, H2 2017 10Number of Products under Development by Companies, H2 2017 The guide covers therapeutics under Development by Companies /Universities /Institutes,

List of TablesNumber of Products under Development for Anesthetic Effect, H2 2017 10Number of Products under Development by Companies, H2 2017

Anesthetic Effect (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is

List of TablesNumber of Products under Development for Anesthetic Effect, H2 2017 10Number of Products under Development by Companies, H2 2017 Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Anesthetic Effect (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Anesthetic Effect (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Anesthetic Effect (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Anesthetic Effect (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Anesthetic Effect (Central Nervous System)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Anesthetic Effect (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Anesthetic Effect (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Anesthetic Effect - Overview
    • Anesthetic Effect - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Anesthetic Effect - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Anesthetic Effect - Companies Involved in Therapeutics Development
    • 4P Therapeutics LLC
    • Biolab Farmaceutica Ltda
    • Crescita Therapeutics Inc
    • Drawbridge Pharmaceuticals Pty Ltd
    • Expanesthetics Inc
    • Jiangsu Hengrui Medicine Co Ltd
    • Lee's Pharmaceutical Holdings Ltd
    • Lipicard Technologies Ltd
    • Paion AG
    • Phosphagenics Ltd
    • Physica Pharma
    • Primex Pharmaceuticals Oy
    • Proteus SA
    • Recro Pharma Inc
    • Taiwan Liposome Company Ltd
    • The Medicines Company
  • Anesthetic Effect - Drug Profiles
    • alphaxalone - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Aom-0765 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • bupivacaine hydrochloride SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Carboetomidate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cysteine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EXPS-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EXPS-05 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EXPS-09 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Flexicaine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • gabafol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HSK-3486 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lidocaine hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lidocaine hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LT-1121 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LT-1123 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Methoxycarbonyl Carboetomidate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Methoxycarbonyl Etomidate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • midazolam hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • neosaxitoxin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PB-5109 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PHY-301 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • propofol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • propofol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • propofol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • propofol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • remimazolam - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • remimazolam - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RP-1000 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RP-2000 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Anesthetic Effect - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit NMDA Receptor for Anesthesia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SPR-819 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Anesthetic Effect - Dormant Projects
  • Anesthetic Effect - Discontinued Products
  • Anesthetic Effect - Product Development Milestones
    • Featured News & Press Releases
      • Mar 09, 2017: China FDA has Approved Zingo for Pediatric Use Needle-free Local Analgesia as Priority Review for Clinical Trial
      • Nov 14, 2016: Powder Pharmaceuticals Submits New Drug Application to China FDA and Hong Kong Department of Health for Needle-free Local Analgesia
      • Oct 19, 2016: Positive Remimazolam Phase III Colonoscopy Results Presented at the 2016 American College of Gastroenterology Annual Scientific Meeting
      • Sep 22, 2016: PAION: Remimazolam Phase III Colonoscopy Data to Be Presented at the American College of Gastroenterology 2016 Meeting
      • Sep 06, 2016: PAION announces clinical development progress with remimazolam by its Partner Yichang Humanwell in China
      • Jun 19, 2016: Paion Reports Positive Remimazolam Headline Data In Pivotal U.S. Phase III Study In Procedural Sedation For Colonoscopy
      • Feb 18, 2016: PAION reports about positive pre-NDA meeting with Japanese authority PMDA
      • Feb 09, 2016: Paion Discontinues European Remimazolam Phase III Trial In Cardiac Surgery Patients Due To Insufficient Recruitment
      • Dec 01, 2015: PAION Announces Initiation of U.S. Clinical Safety Trial of Remimazolam in High Risk Patients Undergoing Colonoscopy
      • Oct 12, 2015: Remimazolam Posters at Anesthesiology 2015
      • Sep 01, 2015: Recently Published Study Shows Positive Results for ZiNGO in Pediatric Patients
      • Aug 11, 2015: Paion Starts EU Phase III Study With Remimazolam In The Indication General Anesthesia
      • Jun 08, 2015: PAION Announces Initiation Of Second U.S. Phase 3 Clinical Trial Of Remimazolam For Procedural Sedation During Bronchoscopy
      • Feb 10, 2015: Drawbridge Pharmaceuticals granted Notice of Allowance for divisional patent in the United States
      • Nov 05, 2014: Paion's Partner Ono Decides Not To File For Regulatory Approval Of REMIMAZOLAM In Japan And Will Return Its REMIMAZOLAM Rights For Japan To Paion
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Anesthetic Effect, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Anesthetic Effect - Pipeline by 4P Therapeutics LLC, H2 2017
  • Anesthetic Effect - Pipeline by Biolab Farmaceutica Ltda, H2 2017
  • Anesthetic Effect - Pipeline by Crescita Therapeutics Inc, H2 2017
  • Anesthetic Effect - Pipeline by Drawbridge Pharmaceuticals Pty Ltd, H2 2017
  • Anesthetic Effect - Pipeline by Expanesthetics Inc, H2 2017
  • Anesthetic Effect - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2017
  • Anesthetic Effect - Pipeline by Lee's Pharmaceutical Holdings Ltd, H2 2017
  • Anesthetic Effect - Pipeline by Lipicard Technologies Ltd, H2 2017
  • Anesthetic Effect - Pipeline by Paion AG, H2 2017
  • Anesthetic Effect - Pipeline by Phosphagenics Ltd, H2 2017
  • Anesthetic Effect - Pipeline by Physica Pharma, H2 2017
  • Anesthetic Effect - Pipeline by Primex Pharmaceuticals Oy, H2 2017
  • Anesthetic Effect - Pipeline by Proteus SA, H2 2017
  • Anesthetic Effect - Pipeline by Recro Pharma Inc, H2 2017
  • Anesthetic Effect - Pipeline by Taiwan Liposome Company Ltd, H2 2017
  • Anesthetic Effect - Pipeline by The Medicines Company, H2 2017
  • Anesthetic Effect - Dormant Projects, H2 2017
  • Anesthetic Effect - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Anesthetic Effect, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top